EAVE II logo

Protocol and analysis

The EAVE II team is committed to openness and transparency. Key information such as the study protocol, statistical analysis plan and code used in analyses are available on this website.

Study Protocol

Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II): protocol for an observational study using linked Scottish national data

Simpson, C.R., Robertson, C., Vasileiou, E., et al.

Available via BMJ Open 2020;10:e039097. DOI: 10.1136/bmjopen-2020-039097

Read the EAVE II protocol (June 2020)

Statistical Analysis Plans (SAPs)

The EAVE II team rapidly reacts to focus on work required to inform policy as the dynamics of the pandemic and vaccine delivery change over time.

As we do so, we will publish details of individual analysis plans, here:

EAVE II SAP for first and second dose COVID-19 vaccine waning in adults (15 March, 2021)

SAP for first dose vaccine failures in adults (27 May, 2021)

SAP for second dose waning (10th September, 2021)

SAP for programmatic evaluation of COVID-19 vaccination against hospitalisations in adults (April 23, 2021)

SAP to investigate effectiveness of COVID-19 vaccines in children and young people (CYP) aged 12 to 17 years in Scotland

SAP for studying the uptake, safety, and effectiveness of monoclonal antibody therapy for COVID-19 (25 February 2022)

Code available in EAVE II GitHub repository

Code used in our analyses are available via the EAVE II GitHub site